NCT06578949CompletedPhase 3
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase 3, Single-arm, Open-label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 28 Aug 2024
- Start date
- 10 Oct 2024
- Primary completion date
- 15 May 2025
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- NCT number
- NCT06578949
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 18
- From 10 Oct 2024 to the primary completion date, 15 May 2025
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Meningitidis infection or unresolved meningococcal disease
- History of bone marrow transplantation
- Other significant systemic diseases that might have impact on efficacy and safety assessment
Who the study is looking for
- Adult C5 inhibitor naive PNH patients (age\>=18), which is confirmed by flow cytometry evaluation.
- Must be vaccinated againast N meningitidis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| - Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| - Coordinator of this site? Confirm its status | Nantong | China | Unknown status |
| - Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| - Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
| - Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.